GlassScriptPhysician profile
Ann-Robert Goode
NPI 1649971441
$2,750.17
in general payments reported to CMS, 2019-2025
13 companies · $933 in 2025
The $933 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $866 · 2024: $951 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.75 |
| Education | $289.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.80 | 2023-2025 | |
| Janssen Biotech, INC. | $698.62 | 2023-2025 | Tremfya |
| Genzyme Corporation | $293.07 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $205.15 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $186.90 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $139.65 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $133.75 | 2024-2025 | |
| Ucb, INC. | $113.48 | 2024-2025 | Bimzelx |
| Amgen INC. | $107.38 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $38.19 | 2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $32.26 | 2025 | Nemluvio |
| Incyte Corporation | $24.75 | 2025 | Opzelura |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann-Robert Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.